Old Web
English
Sign In
Acemap
>
authorDetail
>
Du Hung Lam
Du Hung Lam
Celgene
Azacitidine
Medicine
Pathology
Physical therapy
Oncology
2
Papers
23
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).
2019
Journal of Clinical Oncology
Courtney D. DiNardo
Anthony S. Stein
Eytan M. Stein
Amir T. Fathi
Olga Frankfurt
Andre C. Schuh
Giovanni Martinelli
Prapti A. Patel
Emmanuel Raffoux
Peter Tan
Amer M. Zeidan
Stéphane de Botton
Hagop M. Kantarjian
Richard Stone
Du Hung Lam
Jing Gong
Vickie Zhang
Thomas Winkler
Bin Wu
Paresh Vyas
Show All
Source
Cite
Save
Citations (23)
A randomized, open-label, phase II study of CC-486 (oral azacitidine), alone or in combination with durvalumab (MEDI4736), in patients (pts) with myelodysplastic syndromes (MDS) unresponsive to prior parenteral azacitidine or decitabine.
2016
Journal of Clinical Oncology
Pierre Fenaux
Lewis R. Silverman
Ghulam J. Mufti
John F. Seymour
Rami S. Komrokji
Stefan Faderl
Du Hung Lam
Michele Sharr-McMahon
C.L. Beach
Guillermo Garcia-Manero
Show All
Source
Cite
Save
Citations (0)
1